Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 7Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Breast 3Gynecologic 2Gastrointestinal 2CNS 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Glioblastoma 2Gliosarcoma 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × veliparib × CNS × Clear all
NCT02152982 2026-06-03

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡